Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Bornschein will join the Simmons Group (MRC Human Immunology Unit) for a project developing strategies to identify patients at high risk of gastritis/gastric cancer.

The Clinical Academic Research Partnerships (CARP) scheme aims to support consultants working in public health to enhance their research skillset. The prestigious scheme funded by the Medical Research Council and the National Institute for Health and Care Research, allows research-qualified health professionals to form collaborative, high-quality research partnerships with leading biomedical researchers.

Dr Jan Bornschein, a Consultant Gastroenterologist based at Oxford University Hospitals, will be joining the Intestinal Immunity in Health and Disease Group at the MRC Human Immunology Unit. The research group, led by MRC HIU Director Professor Alison Simmons, investigates the structure and function of the intestine, intestinal immunity, and the pathogenesis of intestinal disease.


After relocating back to the UK from Germany five years ago, I spend my working days in a 100% clinical position, trying to keep my academic spirit alive in my free time. The MRC CARP award will give me the opportunity to get my hands on proper science again and follow my passion in the investigation of gastric inflammation –working in the world-leading environment of the MRC Human Immunology Unit - Dr Jan Bornschein

During the project, Dr Bornschein aims to identify the factors contributing to the development of gastritis and, subsequently, transformation to gastric cancer. This will enable an understanding of individual risk of cancer for each patient to allow tailored scheduling of the investigations needed to aid early detection in patients at higher risk.

See the MRC Weatherall Institute of Molecular Medicine website for the full story.